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Chronic total coronary occlusions (CTO) are encountered
frequently, found in up to 50% of patients with coronary
artery disease (CAD) referred for elective angiography.
Treatment strategy for an individual patient is often
changed on the basis of the presence or absence of a CTO
(1). Percutaneous coronary intervention (PCI) of CTO
remains challenging, with observed success rates that are
significantly lower than those for non-occluded lesions
(2,3). Therefore, it is not surprising that in randomized
trials from the BARI (Bypass Angioplasty Revascularization
Investigation) trial to the SYNTAX (Synergy between PCI
with Taxus and Cardiac Surgery) study, CTO has endured
as the strongest predictor for referral to coronary artery
bypass surgery (CABG) rather than randomization.
See page 952
Despite the challenges of long procedure times, intensive
resource usage, increased radiation and contrast exposure,
and reduced success rates, PCI for CTO remains a viable,
evolving field with continuing advancements in technique,
wires, and catheters and a growing body of published
outcomes reports. Current data suggest that successful PCI
for CTO is associated with improvement in patient symp-
toms, quality of life, left ventricular function, and survival,
compared with those with unsuccessful CTO PCI (2–11).
Whether long-term survival is improved after attempted
CTO PCI remains controversial, because no randomized
trial of CTO PCI versus medical therapy or CABG has ever
been performed. However, indirect data abound and deserve
discussion.
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isclose.An analysis of more than 15,000 patients from the New
York State PCI registry demonstrated that incomplete
revascularization (IR) was related to lower rates of survival
when compared with complete revascularization (12).
Chronic total coronary occlusion was frequently encoun-
tered in the IR cohort and conferred a greater hazard for
death when compared with IR due to subtotal stenoses.
Additionally, van der Schaaf et al. (13) demonstrated that
the presence of a noninfarct-related artery CTO at the time
of primary PCI for ST-segment elevation myocardial in-
farction is an independent predictor of future mortality. In
addition to this indirect evidence, 7 observational studies
have demonstrated significant reductions in mortality with
successful PCI for CTO, compared with unsuccessful at-
tempts (Table 1) (2,3,5–8,10). In addition, a recent meta-
analysis of 13 observational trials also demonstrated a
significant reduction in long-term mortality associated with
successful CTO PCI, compared with failed attempts (14)
A major limitation of these studies is their observational
design, with limited information with regard to potential
baseline differences between the successful versus unsuccess-
ful cohorts. The lack of a true randomized, medically treated
control group brings up the persistent question of whether
the survival benefit demonstrated with successful PCI is, in
fact, related to the beneficial effects of opening a chronically
occluded vessel versus potential harm conferred to those
with failed CTO PCI. Furthermore, it has been hypothe-
sized that failure of CTO PCI is simply a marker for
increasing baseline patient and lesion complexity, and there-
fore the poorer outcomes seen in this group are related to
the baseline burden of disease rather than any beneficial
effect of CTO recanalization.
In this issue of JACC: Cardiovascular Interventions, Meh-
ran et al. (15) report the results of a multicenter observa-
tional study examining long-term clinical outcomes of 1,791
patients after PCI for CTO. This was a large well-executed
study conducted between 1998 and 2007 with expert CTO
operators at highly regarded institutions. An overall proce-
dural success rate of 68% was reported, with success as high
as 81% at 1 site. After multivariate adjustment, successful
CTO PCI was an independent predictor of reduced cardiac
mortality with a strong trend toward lower all-cause mor-
tality. These survival data reinforce the findings of multiple
previous observational studies and emphasize that current
aggressive PCI attempts and re-attempts with stiff wires and
multiple long drug-eluting stents provide excellent long-
term results. Safety and efficacy endpoints with drug-eluting
stents for CTOs in this trial demonstrated low rates of stent
thrombosis and significantly reduced target vessel revascu-
larization, compared with bare-metal stents.
With the existing mature body of observational, “real-
world” registry data and a meta-analysis suggesting that
successful CTO might prolong life, randomized data are
now necessary to further clarify this important issue. A
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963positive randomized trial comparing optimal medical ther-
apy (OMT) with OMT plus CTO PCI using contemporary
techniques would complement existing data and raise the
level of evidence favoring aggressive treatment of CTOs
with PCI. Ideally, this trial would include patients with a
CTO of the proximal or mid left anterior descending
coronary artery or CTO of a large dominant right or
circumflex artery with a moderate-to-large ischemic burden
who have an acceptable amount of angina on medications to
minimize crossovers. After baseline data collection and
consent, patients would be randomized and followed for5
years to tabulate survival and cardiovascular outcomes.
Undoubtedly such a trial will be difficult to conduct for
multiple reasons. Randomization to a therapy with average
success rates in the 75% range will pose a challenge for
intention-to-treat analysis. By selecting sites with expert
CTO operators performing75 CTO PCIs/year, this issue
could potentially be minimized. Conversely, selection bias
directing patients with anatomically favorable CTOs with
large ischemic burdens directly to PCI rather than random-
ization will also have to be monitored and minimized.
The fact that the addition of PCI to OMT for stable
CAD has not previously been shown to improve survival in
randomized trials is an important consideration. However,
CTO has been excluded from these previous trials, and
there is evidence from the COURAGE (Clinical Outcomes
Utilizing revascularization and Aggressive Drug Evaluation)
trial of incremental benefit with PCI with increasing ische-
mic burden in stable CAD patients (16). Substudies assess-
ing ischemic burden, left ventricular function, and quality of
life should be planned, in addition to the evaluation of the
effect of CTO PCI on cardiac and total mortality, myocar-
dial infarction, stroke, target vessel revascularization, and
CABG. We feel strongly that a randomized trial of this
nature would contribute significantly to our understanding
of the importance of CTO and refine our treatment ap-
proach for CTO patients. Unfortunately, a single random-
ized trial with 80% power to show a 25% improvement in
the expected approximately 8% 5-year mortality with OMT
Table 1. Observational Studies Demonstrating Significant Reductions in M
First Author
(Ref. #) n Time Period Follow-Up
Prasad et al. (3) 1,262 1979–2005 Cumulative 10-yr
Suero et al. (2) 2,007 1980–1999 Cumulative 10-yr
Noguchi et al. (10) 226 1986–1996 Cumulative 12-yr
Hoye et al. (8) 874 1992–2002 Cumulative 5-yr
Olivari et al. (5) 369 1999–2000 1-yr
Aziz et al. (7) 543 2000–2004 Cumulative 2-yr
Valenti et al. (6) 486 2003–2006 Cumulative 4-yr
*Approximated from Kaplan-Meier survival curves. After multivariate adjustment, technical failure
CTO chronic total coronary occlusion; PCI percutaneous coronary intervention.would require randomization of5,000 patients. If patient-level data were available and entry criteria were consistent,
survival data could potentially be pooled from multiple
smaller randomized trials separately underpowered for sur-
vival analysis.
Currently, the DECISION-CTO (Drug-Eluting Stent
Implantation Versus Optimal Medical Treatment in Pa-
tients with Chronic Total Occlusion) trial—a randomized
trial of PCI versus medical therapy for CTO with a
noninferiority, composite end-point design and planned
enrollment of 1,100 patients—is being conducted in Asia
and will provide us with the first randomized data on CTO
PCI. More data from randomized trials are clearly needed to
establish the proper positioning of CTO PCI in our
treatment strategy.
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